Cardiol Therapeutics Inc Class A saw a notable decline in its stock price yesterday, raising concerns among investors.
In yesterday's trading session, Cardiol Therapeutics Inc Class A (CRDL.TO) experienced a drop of 3.78%, closing at CA$1.78. This decline comes against a backdrop of mixed news and ongoing developments in the company's clinical trials.
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$216.29M
52W high
$3.23
52W low
$1.23
1W change
-12.32%
Beta
0.72
Analyst Price Targets
Based on analyst covering CRDL · as of Oct 12, 2026
Wall Street analysts forecast CRDL stock price to rise 469.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.00
+469.1% Upside
Previously C$6.00 on Sep 17, 2026
Current Price
C$1.23
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
68.8%
Annualized
90-Day Vol
65.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.13
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.89 | C$1.49 – C$2.39 |
| 60 trading days | C$2.01 | C$1.43 – C$2.80 |
| 90 trading days | C$2.13 | C$1.41 – C$3.21 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should remain cautious as Cardiol Therapeutics navigates its pivotal Phase III MAVERIC trial while facing market volatility.
Stock Price Decline: -3.78%
Cardiol Therapeutics' market cap stands at CA$216 million, indicating the company's vulnerability to market fluctuations.
Bull case
Despite the recent stock decline, Cardiol Therapeutics has made important progress in its clinical trials. These achievements could boost its valuation and restore investor confidence over time.
Bear case
The stock's performance reflects investor skepticism, especially given the inherent risks in the biotech sector and the company's dependence on successful trial outcomes.
Advertisement
Market Reaction to Clinical Developments
Yesterday's decline in Cardiol Therapeutics' stock price may reflect investor concerns about the company's ongoing clinical trials. Even though it hit its enrollment target for the Phase III MAVERIC trial ahead of schedule, the market seems cautious about the effectiveness of CardiolRx™ and its potential impact on future revenues.
Investor Sentiment and Future Outlook
As Cardiol Therapeutics continues to navigate its clinical trials, investor sentiment remains mixed. The recent stock drop highlights the volatility often associated with biotech investments, where trial outcomes can significantly influence stock performance. Investors should weigh the potential for future growth against the risks inherent in the sector.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
